Where does Aclaris Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aclaris Therapeutics, Inc. ranks #14,423 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aclaris Therapeutics, Inc. hold?

Aclaris Therapeutics, Inc. holds 20 US utility patents granted between 2017 and 2025, spanning 7 technology areas.

What is Aclaris Therapeutics, Inc.'s Innovation Score?

Aclaris Therapeutics, Inc. has an Innovation Score of 38.7 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aclaris Therapeutics, Inc. focus on?

Aclaris Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 17 patents, ranking #1,155 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Aclaris Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Aclaris Therapeutics, Inc.'s recent grant velocity is +14% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Aclaris Therapeutics, Inc.'s patents?

Aclaris Therapeutics, Inc.'s patents average 25.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aclaris Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Aclaris Therapeutics, Inc.

USPTO PatentsView assignee record - 20 granted patents across 7 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aclaris ranks #14,423 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 7 technology areas.

#14,423
of 49,997 US assignees by volume: Top 40%
by Innovation Score (38.7/100): 25.8
avg claims per patent: +14%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14423 · US Corporation #14,423 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 20 grants
MID-PACK #14,423/49,997
PHOTO-FINISH Abbott Laboratories…
CPC-NARROW A61P · 7 areas
INNOV-THIN 38.7/100
CLAIMS-DENSE 25.8 claims/avg
TYPE-USCORP US Corporation
VEL-UP +14% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Abbott Laboratories Vascular Enterprises Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aclaris’s 38.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.5 pts (27%) Velocity 3.8 pts (10%) Breadth 9.4 pts (24%) Claim depth 15.0 pts (39%)

Qualcomm Incorporated · highest

85
Aclaris Therapeutics · this assignee

39
3D Lighting… · lowest

7

What this shows Aclaris's Innovation Score is 38.7/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aclaris?

Each dot is one of Aclaris’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aclaris’s own 25.8 claims/patent is ABOVE the 15.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aclaris vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aclaris's grants concentrate

Aclaris Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 85% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2017. By volume, Aclaris sits between Abbott Laboratories Vascular Enterprises Limited and Advanced BioNutrition Corp..

Aclaris's three-year grant acceleration

Aclaris Therapeutics, Inc. shows 4 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Abbott Laboratori…

20
Abyrx

20
Accelerate Diagno…

20
Accutar Biotechno…

20
Actimize

20
Actionpower

20
Additive

20
Advanced Bionutri…

20
Aclaris Therapeut… ◀

20

What this shows Aclaris holds 20 patents at rank #14,448, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aclaris

By rank, the assignees closest to #14,448 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Aclaris's primary technology class.

Aclaris's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Aclaris Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	5.0%
2018	3	15.0%
2019	3	15.0%
2020	3	15.0%
2021	1	5.0%
2023	4	20.0%
2025partial year	5	25.0%

Which technologies does Aclaris Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 17

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 17

C07D - Heterocyclic Compounds 13

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 6

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 4

Y02A - Technologies FOR Adaptation TO Climate Change 3

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aclaris Therapeutics, Inc.'s patent record in context - here's where to go next.

Aclaris Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #14,423 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aclaris Therapeutics, Inc. against Abbott Laboratories Vascular Enterprises Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.